

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purpose only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.



EXTRAWEILL PHARMACEUTICAL HOLDINGS LIMITED

精優藥業控股有限公司*

(Incorporated in Bermuda with limited liability)

(Stock Code: 00858)

ISSUE OF NEW SHARES UNDER GENERAL MANDATE

SUBSCRIPTION AGREEMENT I

On 14 August 2025 (after trading hours), the Company entered into the Subscription Agreement I with the Subscriber I, pursuant to which the Subscriber I has conditionally agreed to subscribe for and the Company has conditionally agreed to allot and issue an aggregate of 30,000,000 Subscription Shares I at the Subscription Price I in the total sum of HK\$2,910,000, equivalent to HK\$0.097 per Subscription Share I. Subscription I under the Subscription Agreement I is subject to satisfaction of the Conditions I.

The Subscription Shares I to be allotted and issued under Subscription I represent (i) approximately 1.26% of the existing issued share capital of the Company as at the date of this announcement; and (ii) approximately 1.24% of the issued share capital of the Company as enlarged by the allotment and issue of the Subscription Shares I (assuming there will be no change in the issued share capital of the Company between the date of this announcement and the Completion I and without taking into account the Subscription Shares II that may be allotted and issued by the Company under the Subscription II and the Subscription Shares III that may be allotted and issued by the Company under the Subscription III).

SUBSCRIPTION AGREEMENT II

On 14 August 2025 (after trading hours), the Company entered into the Subscription Agreement II with the Subscriber II, pursuant to which the Subscriber II has conditionally agreed to subscribe for and the Company has conditionally agreed to allot and issue an aggregate of 20,000,000 Subscription Shares II at the Subscription Price II in the total sum of HK\$1,940,000, equivalent to HK\$0.097 per Subscription Share II. Subscription II is subject to satisfaction of the Conditions II.

The Subscription Shares II to be allotted and issued under Subscription II represent (i) approximately 0.84% of the existing issued share capital of the Company as at the date of this announcement; and (ii) approximately 0.83% of the issued share capital of the Company as enlarged by the allotment and issue of the Subscription Shares II (assuming there will be no change in the issued share capital of the Company between the date of this announcement and the Completion II and without taking into account the Subscription Shares I that may be allotted and issued by the Company under the Subscription I and the Subscription Shares III that may be allotted and issued by the Company under the Subscription III).

SUBSCRIPTION AGREEMENT III

On 14 August 2025 (after trading hours), the Company entered into the Subscription Agreement III with the Subscriber III, pursuant to which the Subscriber III has conditionally agreed to subscribe for and the Company has conditionally agreed to allot and issue an aggregate of 110,000,000 Subscription Shares III at the Subscription Price III in the total sum of HK\$10,670,000, equivalent to HK\$0.097 per Subscription Share III. Subscription III is subject to satisfaction of the Conditions III.

The Subscription Shares III to be allotted and issued under Subscription III represent (i) approximately 4.6% of the existing issued share capital of the Company as at the date of this announcement; and (ii) approximately 4.4% of the issued share capital of the Company as enlarged by the allotment and issue of the Subscription Shares III (assuming there will be no change in the issued share capital of the Company between the date of this announcement and the Completion III and without taking into account the Subscription Shares I that may be allotted and issued by the Company under the Subscription I and the Subscription Shares II that may be allotted and issued by the Company under the Subscription II).

Subscription Shares I, Subscription Shares II and Subscription Shares III will be allotted and issued under the General Mandate, which has not been used since granted.

WARNING

The Subscription I, the Subscription II and the Subscription III are subject to satisfaction of the Conditions I, the Conditions II and the Conditions III respectively and the Subscription I, the Subscription II and/or the Subscription III may or may not proceed. Shareholders and potential investors are advised to exercise caution when dealing in the Shares.

SUBSCRIPTION I

On 14 August 2025 (after trading hours), the Company entered into the Subscription Agreement I with the Subscriber I, pursuant to which the Subscriber I has conditionally agreed to subscribe for and the Company has conditionally agreed to allot and issue an aggregate of 30,000,000 Subscription Shares I at the Subscription Price I in the total sum of HK\$2,910,000, equivalent to HK\$0.097 per Subscription Share I. Subscription I under the Subscription Agreement I is subject to satisfaction of the Conditions I.

Subscription Agreement I

Date: 14 August 2025 (after trading hours)

Parties: Issuer: The Company

The Subscriber I: Tsang Kwong Chiu, Kevin

Subscriber I

To the best knowledge, information and belief of the Directors, having made all reasonable enquiries, Subscriber I, through Master Professional Group Limited, a company incorporated in the British Virgin Islands and wholly owned by Subscriber I, holds 10,330,000 Shares, representing approximately 0.43% of the issued share capital of the Company as at the date of this announcement.

Save as disclosed above, to the best of the Directors' knowledge, information and belief having made all reasonable enquiries, Subscriber I is an Independent Third Party and is independent and not connected to Subscriber II, Subscriber III and their respective associates.

Subscription Shares I

The Subscription Shares I to be allotted and issued under Subscription I represent (i) approximately 1.26% of the existing issued share capital of the Company as at the date of this announcement; and (ii) approximately 1.24% of the issued share capital of the Company as enlarged by the allotment and issue of the Subscription Shares I (assuming there will be no change in the issued share capital of the Company between the date of this announcement and the Completion I and without taking into account the Subscription Shares II that may be allotted and issued by the Company under the Subscription II and the Subscription Shares III that may be allotted and issued by the Company under the Subscription III).

Subscription Price I

The Subscription Price I in the total sum of HK\$2,910,000, equivalent to HK\$0.097 per Subscription Share I, represents:

- (i) a discount of approximately 17.80% to the closing price of HK\$0.118 per Share as quoted on the Stock Exchange on 14 August 2025, being the date of the Subscription Agreement I; and
- (ii) a discount of approximately 19.97% to the average of the closing prices per Share of HK\$0.1212 as quoted on the Stock Exchange for the last five consecutive trading days immediately preceding the date of the Subscription Agreement I.

The aggregate nominal value of the 30,000,000 Subscription Shares I will be HK\$300,000.

The Subscription Price I was arrived at after arm's length negotiation between the Company and the Subscriber I with reference to the recent market prices of the Shares and current market conditions. The Directors consider that the Subscription Price I and the terms of the Subscription Agreement I are fair and reasonable and in the interests of the Company and the Shareholders as a whole.

Conditions I

Completion I is subject to satisfaction of the Conditions I below:

- (i) the Listing Committee of the Stock Exchange having granted approval for the listing of and permission to deal in the Subscription Shares I;
- (ii) all other necessary consents and approvals required to be obtained from any relevant governmental authorities and regulatory bodies on the part of the Company and/or the Subscriber I, if any, for the Subscription Agreement I and the transactions contemplated thereunder, having been obtained and remain in full force and effect; and
- (iii) there has been no material breach of any representations, warranties or agreements by the Company or the Subscriber I.

If the Conditions I are not satisfied on or before the Long Stop Date I, the Subscription Agreement I shall terminate and neither of the Company nor the Subscriber I shall have any claim against the other for costs, damages, compensation or otherwise save for any antecedent breach of the Subscription Agreement I.

As at the date of this announcement, the Conditions I have not been satisfied.

Settlement and satisfaction of the Subscription Price I

The Subscription Price I in the total sum of HK\$2,910,000 will be settled and satisfied by the Subscriber I with the Company in cash at Completion I.

Ranking of the Subscription Shares I

Subscription Shares I will rank, upon issue, *pari passu* in all respect with the Shares in issue on the date of the allotment and issue of the Subscription Shares I.

Completion I

Completion I will take place within 7 Business Days after the Conditions I have been satisfied (or such other date as may be agreed between the Company and the Subscriber I in writing).

The Subscription Agreement I, the Subscription Agreement II and the Subscription Agreement III are not inter-conditional upon each other.

SUBSCRIPTION II

On 14 August 2025 (after trading hours), the Company entered into the Subscription Agreement II with the Subscriber II, pursuant to which the Subscriber II has conditionally agreed to subscribe for and the Company has conditionally agreed to allot and issue an aggregate of 20,000,000 Subscription Shares II at the Subscription Price II in the total sum of HK\$1,940,000, equivalent to HK\$0.097 per Subscription Share II. The Subscription II is subject to satisfaction of the Conditions II.

Subscription Agreement II

Date: 14 August 2025

Parties: Issuer: The Company

The Subscriber II: Zhang Xiaojia

Subscriber II

To the best of the Directors' knowledge, information and belief having made all reasonable enquiries, the Subscriber II is an Independent Third Party and Subscriber II is independent and not connected to Subscriber I, Subscriber III and their respective associates.

As at the date of this announcement, to the best of the Directors' knowledge, information and belief having made all reasonable enquiries, neither the Subscriber II nor her associates hold or are interested in any Share or other securities of the Company.

Subscription Shares II

The Subscription Shares II to be allotted and issued under Subscription II represent (i) approximately 0.84% of the existing issued share capital of the Company as at the date of this announcement; and (ii) approximately 0.83% of the issued share capital of the Company as enlarged by the allotment and issue of the Subscription Shares II (assuming there will be no change in the issued share capital of the Company between the date of this announcement and the Completion II and without taking into account the Subscription Shares I that may be allotted and issued by the Company under the Subscription I and the Subscription Shares III that may be allotted and issued by the Company under the Subscription III).

Subscription Price II

The Subscription Price II in the total sum of HK\$1,940,000, equivalent to HK\$0.097 per Subscription Share II represents:

- (i) a discount of approximately 17.8% to the closing price of HK\$0.118 per Share as quoted on the Stock Exchange on 14 August 2025, being the date of the Subscription Agreement II; and

- (ii) a discount of approximately 19.97% to the average of the closing prices per Share of HK\$0.1212 as quoted on the Stock Exchange for the last five consecutive trading days immediately preceding the date of the Subscription Agreement II.

The aggregate nominal value of the Subscription Shares II will be HK\$200,000.

The Subscription Price II was arrived at after arm's length negotiation between the Company and the Subscriber II with reference to the recent market prices of the Shares and current market conditions. The Directors consider that the Subscription Price II and the terms of the Subscription Agreement II are fair and reasonable and in the interests of the Company and the Shareholders as a whole.

Conditions II

Completion II is subject to satisfaction of the Conditions II as follows:

- (i) the Listing Committee of the Stock Exchange having granted approval for the listing of and permission to deal in the Subscription Shares II;
- (ii) all other necessary consents and approvals required to be obtained from any relevant governmental authorities and regulatory bodies on the part of the Company and/or the Subscriber II, if any, for the Subscription Agreement II and the transactions contemplated thereunder, having been obtained and remain in full force and effect; and
- (iii) there has been no material breach of any representations, warranties or agreements by the Company or the Subscriber II.

If the Conditions II are not satisfied on or before the Long Stop Date II, the Subscription Agreement II shall terminate and neither of the Company nor the Subscriber II shall have any claim against the other for costs, damages, compensation or otherwise save for any antecedent breach of the Subscription Agreement II.

As at the date of this announcement, the Conditions II have not been satisfied.

Settlement and satisfaction of the Subscription Price II

The Subscription Price II in the total sum of HK\$1,940,000, will be settled and satisfied by the Subscriber II with the Company in cash at Completion II.

Ranking of the Subscription Shares II

Subscription Shares II will rank, upon issue, *pari passu* in all respect with the Shares in issue on the date of the allotment and issue of the Subscription Shares II.

Completion II

The Completion II will take place within 7 Business Days after the Conditions II have been satisfied (or such other date as may be agreed between the Company and the Subscriber II in writing).

The Subscription Agreement I, the Subscription Agreement II and the Subscription Agreement III are not inter-conditional upon each other.

SUBSCRIPTION III

On 14 August 2025 (after trading hours), the Company entered into the Subscription Agreement III with the Subscriber III, pursuant to which the Subscriber III has conditionally agreed to subscribe for and the Company has conditionally agreed to allot and issue an aggregate of 110,000,000 Subscription Shares III at the Subscription Price III in the total sum of HK\$10,670,000, equivalent to HK\$0.097 per Subscription Share III. The Subscription III is subject to satisfaction of the Conditions III.

Subscription Agreement III

Date: 14 August 2025 (after trading hours)

Parties: Issuer: The Company

The Subscriber III: Fudan Health International Ltd.

Subscriber III

To the best of the Directors' knowledge, information and belief having made all reasonable enquiries, the Subscriber III is principally engaged in the business involving investment in stocks and shares for medium and long term capital appreciation. The Subscriber III is wholly and beneficially owned by Zhu XiaoMei and the Subscriber III and its ultimate beneficial owner are Independent Third Parties and each of them is independent and not connected to Subscriber I, Subscriber II and their respective associates.

To the best of the Directors' knowledge, information and belief having made all reasonable enquiries, neither the Subscriber III, Zhu XiaoMei nor their respective associates hold or are interested in any Share or other securities of the Company.

Subscription Shares III

The Subscription Shares III to be allotted and issued under Subscription III represent (i) approximately 4.6% of the existing issued share capital of the Company as at the date of this announcement; and (ii) approximately 4.4% of the issued share capital of the Company as enlarged by the allotment and issue of the Subscription Shares III (assuming there will be no change in the issued share capital of the Company between the date of this announcement and the Completion III and without taking into

account the Subscription Shares I that may be allotted and issued by the Company under the Subscription I and the Subscription Shares II that may be allotted and issued by the Company under the Subscription II).

Subscription Price III

The Subscription Price III in the total sum of HK\$10,670,000, equivalent to HK\$0.097 per Subscription Share III represents:

- (i) a discount of approximately 17.80% to the closing price of HK\$0.118 per Share as quoted on the Stock Exchange on 14 August 2025, being the date of the Subscription Agreement III; and
- (ii) a discount of approximately 19.97% to the average of the closing prices per Share of HK\$0.1212 as quoted on the Stock Exchange for the last five consecutive trading days immediately preceding the date of the Subscription Agreement III.

The aggregate nominal value of the 110,000,000 Subscription Shares III will be HK\$1,100,000.

The Subscription Price III was arrived at after arm's length negotiation between the Company and the Subscriber III with reference to the recent market prices of the Shares and current market conditions. The Directors consider that the Subscription Price III and the terms of the Subscription Agreement III are fair and reasonable and in the interests of the Company and the Shareholders as a whole.

Conditions III

Completion III is subject to satisfaction of the Conditions III as follows:

- (i) the Listing Committee of the Stock Exchange having granted approval for the listing of and permission to deal in the Subscription Shares III;
- (ii) all other necessary consents and approvals required to be obtained from any relevant governmental authorities and regulatory bodies on the part of the Company and/or the Subscriber III, if any, for the Subscription Agreement III and the transactions contemplated thereunder, having been obtained and remain in full force and effect; and
- (iii) there has been no material breach of any representations, warranties or agreements by the Company or the Subscriber III.

If the Conditions III are not satisfied on or before the Long Stop Date III, the Subscription Agreement III shall terminate and neither of the Company nor the Subscriber III shall have any claim against the other for costs, damages, compensation or otherwise save for any antecedent breach of the Subscription Agreement III.

As at the date of this announcement, the Conditions III have not been satisfied.

Settlement and satisfaction of the Subscription Price III

The Subscription Price III in the total sum of HK\$10,670,000 will be settled and satisfied by the Subscriber III with the Company in cash at Completion III.

Ranking of the Subscription Shares III

Subscription Shares III will rank, upon issue, *pari passu* in all respect with the Shares in issue on the date of the allotment and issue of the Subscription Shares III.

Application for listing

The Company will apply to the Stock Exchange for the listing of, and permission to deal in, the Subscription Shares III.

Completion III

The Completion III will take place within 7 Business Days after the Conditions III have been satisfied (or such other date as may be agreed between the Company and the Subscriber III in writing).

The Subscription Agreement I, the Subscription Agreement II and the Subscription Agreement III are not inter-conditional upon each other.

APPLICATION FOR LISTING

The Company will apply to the Stock Exchange for the listing of, and permission to deal in, the Subscription Shares I, the Subscription Shares II and the Subscription Shares III.

GENERAL MANDATE

The Subscription Shares I, the Subscription Shares II and the Subscription Shares III will be allotted and issued under the General Mandate granted to the Directors by resolution of the Shareholders passed at the AGM, subject to the limit up to 20% of the then issued share capital of the Company as at the date of the AGM. Under the General Mandate, the Company is authorised to issue up to 478,000,000 new Shares, representing 20% of the issued share capital of the Company as at the date of the passing of the resolution of 2,390,000,000 Shares. Up to the date of this announcement, no new Share has been issued under the General Mandate and 478,000,000 new Shares are available for subscription. Accordingly, the allotment and issue of the Subscription Shares I, the Subscription Shares II and the Subscription Shares III are not subject to the approval of the Shareholders.

INFORMATION OF THE COMPANY AND THE GROUP

The Company is an investment holding company and the Group is principally engaged in the development, manufacture and sales of pharmaceutical products in PRC, and the marketing and distribution of imported pharmaceutical products to customers in PRC.

REASONS FOR THE SUBSCRIPTION I, THE SUBSCRIPTION II AND THE SUBSCRIPTION III AND USE OF PROCEEDS

The Group is principally engaged in the development, manufacture and sales of pharmaceutical products in PRC, and the marketing and distribution of imported pharmaceutical products to customers in PRC.

Assuming that all the Subscription Shares I are successfully issued, the gross proceeds and net proceeds (after deducting the professional fees and all related expenses) from the issue of the Subscription Shares I will be approximately HK\$2,910,000 and HK\$2,890,000 respectively.

Assuming that all the Subscription Shares II are successfully issued, the gross proceeds and net proceeds (after deducting the professional fees and all related expenses) from the issue of the Subscription Shares II will be approximately HK\$1,940,000 and HK\$1,930,000 respectively.

Assuming that all the Subscription Shares III are successfully issued, the gross proceeds and net proceeds (after deducting the professional fees and all related expenses) from the issue of the Subscription Shares III will be approximately HK\$10,670,000 and HK\$10,600,000 respectively.

The Company intends to use the net proceeds from the Subscriptions for the Group's potential new business endeavor into the businesses of trading, manufacturing, sales and distribution of the healthcare products, devices and technologies in the PRC as well as to expand the business opportunities related to the healthcare fields into the overseas markets while the Group will continue to maintain and develop its existing pharmaceutical businesses by allocating its existing internally generated cash resources. The Group believes that the healthcare industry will continue to experience growth in demand for products and solutions that can improve health and patient care due to multiple factors including an aging population, increasing prevalence of chronic diseases, rising health awareness and advancement in technology. The net proceeds from the Subscriptions can support the Group to be in a better position to grasp the business opportunities in the new endeavor.

The Directors consider that the Subscriptions show the confidence of the respective Subscriber I, the Subscriber II and Subscriber III in the business and future development of the Group. It also represents a good opportunity to raise additional funds under the prevailing market conditions that will strengthen the financial position of the Group, broaden the Shareholder's base and provide financial flexibility for potential business opportunities and business expansion which shall strengthen the foundation for the Company's future development. The Directors are of the view that the terms (including but not limited to the subscription price) of each of the Subscription Agreement I, the Subscription Agreement II and the Subscription Agreement III are on normal commercial terms and are fair and reasonable and the Subscriptions are in the interests of the Company and the Shareholders as a whole.

FUND RAISING ACTIVITY OF THE COMPANY IN THE PAST TWELVE MONTHS

The Company had not conducted any equity fund raising activity in the past 12 months immediately preceding the date of this announcement.

EFFECT ON SHAREHOLDING STRUCTURE OF THE COMPANY

For illustration purposes only, set out below are the shareholding structure of the Company (i) as at the date of this announcement; and (ii) immediately after Completion I (assuming there will be no change in the total number of issued Shares between the date of this announcement up to the Completion I other than as a result of the allotment and issue of the Subscription Shares I at Completion I); (iii) immediately after Completion II (assuming there will be no change in the total number of issued Shares between the date of this announcement up to the Completion II other than as a result of the allotment and issue of the Subscription Shares II at Completion II); (iv) immediately after Completion III (assuming there will be no change in the total number of issued Shares between the date of this announcement up to the Completion III other than as a result of the allotment and issue of the Subscription Shares III at Completion III); and (v) immediately after the completion of the Subscriptions (assuming there will be no change in the total issued Shares between the date of this announcement up to the completion of the Subscriptions other than as a result of the allotment and issue of the Subscription Shares I, the Subscription Shares II and the Subscription Shares III):

Shareholders	As at the date of this announcement		immediately after Completion I (assuming there will be no change in the total number of issued Shares between the date of this announcement up to the Completion I other than as a result of the allotment and issue of the Subscription Shares I at Completion I)		immediately after Completion II (assuming there will be no change in the total number of issued Shares between the date of this announcement up to the Completion II other than as a result of the allotment and issue of the Subscription Shares II at Completion II)		immediately after Completion III (assuming there will be no change in the total number of issued Shares between the date of this announcement up to the Completion III other than as a result of the allotment and issue of the Subscription Shares III at Completion III)		immediately after the completion of the Subscriptions (assuming there will be no change in the total number of issued Shares between the date of this announcement up to the completion of the Subscriptions other than as a result of the allotment and issue of the Subscription Shares I, the Subscription Shares II and the Subscription Shares III)	
			Number of		Number of		Number of		Number of	
	Shares	Approx. %	Shares	Approx. %	Shares	Approx. %	Shares	Approx. %	Shares	Approx. %
Cheng Yong (<i>Note 1</i>)	6,980,000	0.29	6,980,000	0.29	6,980,000	0.29	6,980,000	0.28	6,980,000	0.27
Shi Xuanmin	289,700,000	12.12	289,700,000	11.97	289,700,000	12.02	289,700,000	11.59	289,700,000	11.36
Mao Yumin	189,920,000	7.95	189,920,000	7.85	189,920,000	7.88	189,920,000	7.60	189,920,000	7.45
Subscriber I	10,330,000	0.43	40,330,000	1.67	10,330,000	0.43	10,330,000	0.41	40,330,000	1.58
Subscriber II	—	—	—	—	20,000,000	0.83	—	—	20,000,000	0.79
Subscriber III	—	—	—	—	—	—	110,000,000	4.40	110,000,000	4.31
Other public Shareholders	<u>1,893,070,000</u>	<u>79.21</u>	<u>1,893,070,000</u>	<u>78.22</u>	<u>1,893,070,000</u>	<u>78.55</u>	<u>1,893,070,000</u>	<u>75.72</u>	<u>1,893,070,000</u>	<u>74.24</u>
Total	<u><u>2,390,000,000</u></u>	<u><u>100</u></u>	<u><u>2,420,000,000</u></u>	<u><u>100</u></u>	<u><u>2,410,000,000</u></u>	<u><u>100</u></u>	<u><u>2,500,000,000</u></u>	<u><u>100</u></u>	<u><u>2,550,000,000</u></u>	<u><u>100</u></u>

Note 1: Mr. Cheng Yong, an executive Director, holds 830,000 Shares by himself, 1,060,000 Shares through Merchandise Holdings Limited, a company wholly owned by him and 5,090,000 Shares through his spouse.

WARNING

The Subscription I, the Subscription II and the Subscription III are subject to satisfaction of the Conditions I, the Conditions II and the Conditions III respectively and the Subscription I, the Subscription II and/or Subscription III may or may not proceed. Shareholders and potential investors are advised to exercise caution when dealing in the Shares.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following expressions shall have the following meanings when used herein:

“AGM”	the annual general meeting of the Company held on 23 August 2024
“associate(s)”	has the meaning ascribed thereto under the Listing Rules
“Board”	the board of Directors
“Business Day”	a day (excluding Saturdays, Sundays and public holidays) on which banks are generally open for business in Hong Kong
“Company”	Extrawell Pharmaceutical Holdings Limited, a company incorporated in Bermuda with limited liability and the issued Shares of which are listed on the Main Board of the Stock Exchange (stock code: 858)
“Completion I”	completion of the Subscription I pursuant to the Subscription Agreement I
“Completion II”	completion of the Subscription II pursuant to the Subscription Agreement II
“Completion III”	completion of the Subscription III pursuant to the Subscription Agreement III
“Conditions I”	conditions to Completion I as set out in the paragraph headed “Conditions I” of this announcement
“Conditions II”	conditions to Completion II as set out in the paragraph headed “Conditions II” of this announcement
“Conditions III”	conditions to Completion III as set out in the paragraph headed “Conditions III” of this announcement
“connected person(s)”	has the meaning ascribed thereto under the Listing Rules
“Director(s)”	the director(s) of the Company

“General Mandate”	the mandate granted to the Directors by the Shareholders at the AGM to allot, issue and deal with additional Shares not exceeding 20% of the then issued share capital of the Company as at the date of the AGM
“Group”	the Company and its subsidiaries
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Independent Third Party(ies)”	third party(ies) independent of the Company and connected persons of the Company
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“Long Stop Date I”	29 August 2025
“Long Stop Date II”	29 August 2025
“Long Stop Date III”	29 August 2025
“PRC”	the People’s Republic of China
“Share(s)”	ordinary share(s) with a nominal value of HK\$0.01 each in the capital of the Company
“Shareholder(s)”	holder(s) of the issued Shares
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Subscriber I”	Tsang Kwong Chiu, Kevin
“Subscriber II”	Zhang Xiaojia
“Subscriber III”	Fudan Health International Ltd., a company incorporated in the British Virgin Islands with limited liability
“Subscriptions”	collectively, the Subscription I, the Subscription II and the Subscription III
“Subscription I”	the subscription by the Subscriber I from the Company of the Subscription Shares I pursuant to the terms of the Subscription Agreement I

“Subscription II”	the subscription by the Subscriber II from the Company of the Subscription Shares II pursuant to the terms of the Subscription Agreement II
“Subscription III”	the subscription by the Subscriber III from the Company of the Subscription Shares III pursuant to the terms of the Subscription Agreement III
“Subscription Agreement I”	the conditional subscription agreement entered into between the Company and the Subscriber I dated 14 August 2025 in relation to the Subscription I
“Subscription Agreement II”	the conditional subscription agreement entered into between the Company and the Subscriber II dated 14 August 2025 in relation to the Subscription II
“Subscription Agreement III”	the conditional subscription agreement entered into between the Company and the Subscriber III dated 14 August 2025 in relation to the Subscription III
“Subscription Price I”	The total sum of HK\$2,910,000, equivalent to HK\$0.097 per Subscription Share I
“Subscription Price II”	The total sum of HK\$1,940,000, equivalent to HK\$0.097 per Subscription Share II
“Subscription Price III”	The total sum of HK\$10,670,000, equivalent to HK\$0.097 per Subscription Share III
“Subscription Share(s) I”	30,000,000 new Shares to be subscribed by the Subscriber I at the Subscription Price I and to be allotted and issued by the Company pursuant to the Subscription Agreement I
“Subscription Share(s) II”	20,000,000 new Shares to be subscribed by the Subscriber II at the Subscription Price II and to be allotted and issued by the Company pursuant to the Subscription Agreement II
“Subscription Share(s) III”	110,000,000 new Shares to be subscribed by the Subscriber III at the Subscription Price III and to be allotted and issued by the Company pursuant to the Subscription Agreement III

“%”

per cent

By order of the Board
Extrawell Pharmaceutical Holdings Limited
Xie Yi
Chairman

Hong Kong, 14 August 2025

As at the date of this announcement, the executive directors are Dr. Xie Yi, Mr. Cheng Yong, Dr. Lou Yi, Ms. Wong Sau Kuen and Dr. Guo Yi, and the independent non-executive directors are Mr. Fang Lin Hu, Ms. Jin Song and Dr. Zeng Li.

** For identification purpose only*